Page last updated: 2024-12-07

n-(7-(4-nitrobenzo-2-oxa-1,3-diazole))-6-aminocaproyl sphingosine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

N-(7-(4-nitrobenzo-2-oxa-1,3-diazole))-6-aminocaproyl sphingosine: fluorescent ceramide analog; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

N-{6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoyl}sphingosine : An N-acylsphingosine that is sphingosine with the amino nitrogen converted into a 6-{[N-(7-nitrobenzo-2,1,3-oxadiazol-4-yl)amino]}hexananamido group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID16219783
CHEMBL ID135464
CHEBI ID59429
SCHEMBL ID16216321
MeSH IDM0114548

Synonyms (33)

Synonym
n-(nbd-aminohexanoyl)sphingosine
c6-nbd-cer
CHEMBL135464
c6-nbd-ceramide
n-{6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanoyl}sphingosine
nbd-ceramide
86701-10-2
nbd-c6-cer
n-(7-(4-nitrobenzo-2-oxa-1,3-diazole))-6-aminocaproyl sphingosine
6-((n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl)sphingosine
CHEBI:59429 ,
n-(nbd-aminohexanoyl) d-erythro-sphingosine
nbd-c 6cer
94885-02-6
c-6 nbd ceramide
EPITOPE ID:131179
n-(nbd-aminohexanoyl)-d-erythro-sphingosine
SCHEMBL16216321
c6 nbd ceramide
c6-nbd ceramide
Q27126704
hexanamide,n-[(1s,2r,3e)-2-hydroxy-1-(hydroxymethyl)-3-heptadecenyl]-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-
(6-((n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)hexanoyl)sphingosine)
n-[(e,2s,3r)-1,3-dihydroxyoctadec-4-en-2-yl]-6-[(4-nitro-2,1,3-benzoxadiazol-7-yl)amino]hexanamide
39zcu6eb2e ,
n-(6-((7-nitro-2-1,3-benzoxadiazol-4-yl)amino)hexanoyl)-d-erythro-sphingosine
hexanamide, n-((1s,2r,3e)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl)-6-((7-nitro-2,1,3-benzoxadiazol-4-yl)amino)-
unii-39zcu6eb2e
n-((1s,2r,3e)-2-hydroxy-1-(hydroxymethyl)-3-heptadecen-1-yl)-6-((7-nitro-2,1,3-benzoxadiazol-4-yl)amino)hexanamide
n-[(2s,3r,4e)-1,3-dihydroxy-4-octadecen-2-yl]-6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexanamide
DTXSID501334180
HY-W356116
CS-0467369
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
fluorescent probeA role played by a fluorescent molecular entity used to study the microscopic environment by fluorescence spectroscopy.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
N-acylsphingosineThe parent compounds of the ceramide family, composed of sphingosine having an unspecified fatty acyl group attached to the nitrogen.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID221480Inability to reverse inhibitory effect of D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol(PDMP) on accelerated axonal growth of hippocampal neurons, number of axonal branch points/ cell at 51 hour (P value)2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Synthesis and biological evaluation of ceramide analogues with substituted aromatic rings or an allylic fluoride in the sphingoid moiety.
AID221481Evaluation for reversing the inhibitory effects of Fumonisin B1(FB1) on accelerated axonal growth of hippocampal neurons. 2000Journal of medicinal chemistry, Nov-02, Volume: 43, Issue:22
Synthesis and biological evaluation of ceramide analogues with substituted aromatic rings or an allylic fluoride in the sphingoid moiety.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (77)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (6.49)18.7374
1990's38 (49.35)18.2507
2000's21 (27.27)29.6817
2010's11 (14.29)24.3611
2020's2 (2.60)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (2.56%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other76 (97.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]